Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 9607760.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The E6 oncoprotein derived from tumour-associated human papillomaviruses (HPVs) binds to and induces the degradation of the cellular tumour-suppressor protein p53. A common polymorphism that occurs in the p53 amino-acid sequence results in the presence of either a proline or an arginine at position 72. The effect of this polymorphism on the susceptibility of p53 to E6-mediated degradation has been investigated and the arginine form of p53 was found to be significantly more susceptible than the proline form. Moreover, allelic analysis of patients with HPV-associated tumours revealed a striking overrepresentation of homozygous arginine-72 p53 compared with the normal population, which indicated that individuals homozygous for arginine 72 are about seven times more susceptible to HPV-associated tumorigenesis than heterozygotes. The arginine-encoding allele therefore represents a significant risk factor in the development of HPV-associated cancers.
Medical subject headings
- DNA-Binding Proteins
- Papillomaviridae
- Papillomavirus Infections
- Polymorphism, Genetic
- Repressor Proteins
- Tumor Suppressor Protein p53
- Tumor Virus Infections